ReviewClinical and experimental rheumatology2022
Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management.
Review in Clinical and experimental rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Assessing theRMD open · 2025Pooled it
- 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.Arthritis & rheumatology (Hoboken, N.J.) · 2024Guideline
- 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.Arthritis care & research · 2024Guideline
- Systemic Autoimmune Rheumatic Disease-Associated Interstitial Lung Disease: A Pulmonary Perspective on Recent Guidelines.Advances in therapy · 2026Review
- Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Juvenile Dermatomyositis Presenting With Predominant Joint Contractures.Revista de neurologia · 2026Article
- Prognostic Value of Bronchoalveolar Lavage in Systemic Autoimmune Rheumatic Diseases-Associated Interstitial Lung Disease.Journal of clinical medicine · 2026Article
- A transfer learning-based multimodal model for early prediction of 90-day respiratory failure in dermatomyositis-associated interstitial lung disease.Frontiers in immunology · 2026Article
- A non-radioactive modified immunoprecipitation assay for diagnostic detection of anti-MDA5 antibodies in idiopathic inflammatory myopathies.Frontiers in immunology · 2026Article
- Pulmonary Disease in the Older Adult: A Review of Interstitial Lung Disease.Clinics in geriatric medicine · 2025Review
- Epidemiology of Dermatomyositis and Other Idiopathic Inflammatory Myopathies in Northern Spain.Biomedicines · 2025Article
- The Clinical Features and Prognosis of Idiopathic and Infection-Triggered Acute Exacerbation of Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: A Preliminary Study.Diagnostics (Basel, Switzerland) · 2025Article
- Pathophysiological Insights and Clinical Management Strategies for Interstitial Lung Diseases.Biomolecules & therapeutics · 2025Review
- Long-term clinical prognosis of anti-aminoacyl-tRNA synthetase antibodies and interstitial lung disease.Clinical rheumatology · 2025Article
- Article
- Antimelanoma differentiation-associated gene 5 (anti-MDA5) antibody-positive dermatomyositis: clinical features and outcomes in a racially diverse patient cohort.BMC rheumatology · 2025Article
- Clinical, functional, and computed tomographic characterization of idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective cohort study.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025Article
- Occupational and Hobby Exposures Associated With Myositis Phenotypes in a National Myositis Patient Registry.Arthritis care & research · 2025Article
- Clinical impact of pneumomediastinum in patients with myositis-associated interstitial lung disease.PloS one · 2025Article
- Design of a randomised controlled hybrid trial of nintedanib in patients with progressive myositis-associated interstitial lung disease.BMC pulmonary medicine · 2024Article
- Myositis-Associated Interstitial Lung Disease: The Experience of a Tertiary Center.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Interstitial lung disease (ILD) frequently complicates the inflammatory myopathies and at times is the most prominent clinical feature. Over the years, there has been a growing recognition for the strong association between seropositivity of several myositis-specific antibodies (MSAs) and lung involvement. Growing literature suggests that individual MSAs may influence the risk of developing ILD and are associated with pulmonary disease severity and various clinical sub-phenotypes. The presence of ILD in patients with myositis correlates with increased morbidity and mortality. As such, it presents a unique treatment challenge for both the rheumatology and pulmonary communities and requires a multidisciplinary approach to management. This review will discuss the role of serologies and invasive and non-invasive testing modalities utilised to diagnose and monitor patients with myositis-ILD. Current studies pertaining to the wide array of immunomodulatory therapies utilised in cases of progressive disease are also highlighted in detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.